The b 1 -adrenoceptor is a candidate gene for obesity because of its role in catecholamine-induced energy homeostasis. A common Arg 389 Gly variant polymorphism has been shown in recombinant cells to influence its-coupling properties. OBJECTIVE: To investigate the effect of the Arg 389 Gly b 1 -adrenoceptor polymorphism on catecholamine-induced lipolysis in native human fat cells obtained by subcutaneous biopsy. SUBJECTS: Two-hundred and ninety-eight apparently healthy male and female subjects with a wide variation in body mass index (BMI, 18 -60 kg=m 2 ). MEASURES: The lipolytic sensitivities and maximum lipolytic action of noradrenaline and the selective adrenoceptor agonists dobutamine (b 1 ), terbutaline (b 2 ) and CGP 12177 (b 3 ) were determined in isolated subcutaneous adipocytes and related to badrenoceptor radioligand binding parameters. RESULTS: No differences in the sensitivity or maximum lipolytic capacity of the agonists were found between the genotypes. This was true both when all subjects were analyzed together and when subgroups (lean, obese, men, women) were analyzed separately. Radioligand binding to b 1 -or b 2 -adrenoceptors was also similar between genotypes. The polymorphism had no important influence on either BMI or the distribution of obese and non-obese subjects between the genotypes. CONCLUSION: The distribution of the Arg 389 Gly polymorphism is similar in lean and obese subjects and has no apparent effect on the lipolytic response to b-adrenergic stimulation in native human adipocytes. This suggests, despite the altered coupling properties reported in recombinant cells, that the Arg 386 Gly polymorphism has no important influence on human obesity.
Introduction
The susceptibility to common familial disorders such as obesity may involve genetic polymorphisms in G-protein signaling pathways. 1 The b 1 -adrenergic receptor is an attractive candidate gene for obesity because of its important role in energy homeostasis. Among other things, the b 1 -adrenoceptor promotes the lipolytic action of catecholamines in human fat cells, where it co-exists with the other two badrenoceptor subtypes and the anti-lipolytic a 2 -adrenoceptor. 2 Disturbances in catecholamine-induced lipolysis are frequently observed in obesity. 2 A common amino acid variant of the b 1 -adrenoceptor due to a G=C nucleic acid substitution at position 1165 has been described. 3 Variations between the neutral glycine and positively charged arginine at this residue of the receptor are predicted to differentially affect b 1 -adenergic receptor coupling to the G s -alpha protein and thereby subsequent intracellular signaling. 4 Indeed, enhanced coupling to the G s -alpha protein and increased adenylyl cyclase activation was found with the Arg-389 receptor as compared to the Gly-389 receptor in CHW-112 cells transfected with the two variants. 5 It is unknown, however, whether the polymorphism alters lipolysis or binding in native human fat cells. We therefore investigated the lipolytic effects and binding of b-adrenergic agonists and antagonists in 298 apparently healthy subjects of both sexes and a wide variation in body mass index (BMI). We hypothesized that if the native Arg 389 Gly polymorphism is important for human fat cell function then it should influence catecholamine-induced lipolysis and possibly also b-adrenoceptor number in these cells.
Methods

Subjects
The cohort comprised 298 consecutively recruited subjects of Scandinavian origin, who had participated in an ongoing study of the genetic influence on catecholamine-induced lipolysis in fat cells. The study comprised healthy nonobese volunteers (n ¼ 157) who were enrolled through local advertisements and obese, otherwise healthy subjects who had been referred to our obesity unit for treatment (n ¼ 141). All subjects lived in the area around the hospital. None of the subjects were completely sedentary, involved in sporting activities or had undertaken a slimming diet during the last 6 months. Obesity was defined according to WHO (BMI > 30 kg=m 2 ). None were taking regular medication. Ninety men and 208 women were included ranging in age from 19 to 72 y. Fifteen women were menopausal. The subjects came to the laboratory in the morning after an overnight fast. Height, weight and waist-to-hip ratio (WHR) were determined and an antecubital venous blood sample obtained and frozen at 720 C. Finally, a subcutaneous fat biopsy (about 1 -3 g in lean and 2 -4 g in obese subjects) was obtained under local anesthesia from the umbilical region. The study was approved by the hospital's committee on ethics. It was explained in detail to each subject and informed consent was obtained.
Fat cell lipolysis experiments
Experiments were performed on all subjects and were conducted and analyzed as described in detail elsewhere. 6 In brief, isolated fat cells were prepared and their average size, volume and weight determined. Dilute fat cell suspensions (2%, v=v) were incubated in duplicate for 2 h at 37 C in a Krebs -Henseleit phosphate (KRP) buffer (pH 7.4) containing bovine albumin (20 g=l), glucose (1 mg=ml) and ascorbic acid (0.1 mg=ml). At the end of the incubation, an aliquot of the medium was removed for analysis of glycerol (lipolysis index) and the amount of glycerol release related to the number of incubated fat cells.
The following agents were added at various concentrations (10 710 -10 73 mol=l, depending on the type of agent) to the incubation medium at the start of the experiment, including noradrenaline, dobutamine (a selective b 1 -adrenoceptor agonist), terbutaline (a selective b 2 -adrenoceptor agonist) and CGP 12177 (a selective b 3 -adrenoceptor agonist).
Since human subcutaneous fat cells have functional spare b-adrenergic receptors 7 it is possible to use classical pharmacological methods to evaluate receptor function. 8 The concentration response curves were analyzed for pD 2 (negative logarithm of half-maximum effective concentration, EC 50 ) and responsiveness (glycerol release at maximum effective drug concentration). Changes in pD 2 reflect receptor events (binding and coupling to effector) whereas changes in responsiveness reflect more distal and post-receptor related events. 8 A plateau of response was reached at the highest concentrations in all cases and with all drugs.
Radioligand binding
Radioligand binding studies, because of the large amount of tissue required, described elsewhere, 6 were carried out in only 74 subjects. In brief, isolated fat cells ( $ 20 000 cells=ml) ml) were incubated in duplicate in KRP buffer (pH 7.4) with bovine albumin (5 g=l), glucose (1 g=l), ascorbic acid (0.1 g=l) and the non-selective b 1 =b 2 -adrenergic receptor antagonist 125 I-cyanopindolol. Increasing concentrations of radioligand were used in saturation experiments (to determine total b 1 =b 2 -adrenoceptor binding). In competition experiments (to determine affinity and proportions of b 1 -and b 2 -adrenoceptor subtypes), fixed concentrations of radioligand and increasing concentrations of the b-adrenoceptor antagonist ICI 118 555 were used. The latter ligand binds to b 1 -adrenoceptors with low and to b 2 -adrenoceptor with high affinity.
Specific radioligand binding was determined and saturation experiments evaluated for total binding capacity and affinity (K d ) of the radioligand using linear regression analysis of Scatchard plots. 9 The competition experiments were evaluated for the binding constants of high affinity receptor (K d -high representing b 2 -adrenoceptors and K d -low representing b 1 -adrenoceptors) and for the proportion of b 2 -adrenoceptors to the total amount of b 1 =b 2 -adrenoceptors. The computer program LIGAND, which is based on a nonlinear least squares fitting method, 10 was used to analyze competition data. Total radioligand binding was expressed per number of fat cells.
Genotyping DNA was prepared from frozen (720 C) venous blood. The Arg 389 Gly polymorphism in the b 1 -adrenoceptor gene was determined exactly as described. 3 A combination of polymerase chain reaction (PCR) and digestion of the PCR product with the restriction enzyme BcgI was used. However, we slightly modified the PCR primers with the forward primer 5 0 -CTCTGCTGGCTGCCCTTCTTC and the reverse primer 5 0 -GGGCTTCGAGTTCACC-TGCTATC in 3% DMSO and 1.0 mmol=l MgCl 2 , followed by digestion with BcgI.
Statistical analysis
The analyses of phenotypic values were performed by descriptive statistics (mean AE standard deviation by genotype), w 2 analysis and analysis of covariance (ANCOVA) adjusting for sex, age and obesity. Because of the bimodal b b 1 -Receptor polymorphism and adipocytes M Rydén et al distribution of BMI, the analysis of variance could not use BMI as a continuous independent variable. Therefore obese=non-obese was used as an independent categorical variable. The Fisher PLSD test was used for post-hoc analysis.
Results
Genotyping data
When PCR fragments using DNA from different subjects were amplified by the primers described in Methods and subsequently digested by BcgI, three different patterns were obtained on agarose gels. These were identical to those described earlier. 3 Gly 389 homozygotes had a single 530 bp fragment, heterozygotes showed the additional appearance of 342 and 154 bp fragments, and Arg 389 homozygotes a loss of the 530 bp fragment and appearance of the 340 and 154 bp fragments.
To confirm determination of the polymorphism on codon 389, PCR products from randomly chosen subjects with either genotype were submitted to direct sequencing (Cybergene, Stockholm, Sweden). The sequencing data were in accordance with our own genotyping results.
Clinical data
The clinical characteristics of all subjects are shown in Table  1 . Because the sample consisted of subjects of both sexes with large differences in BMI we corrected for both gender and obesity in the statistical analysis. A correction was also made for age. The frequencies of Arg 389 Arg, Arg 389 Gly and Gly 389 Gly were 51, 38 and 11%, respectively. This was not different from that predicted by the Hardy -Weinberg equilibrium hypothesis. Neither gender or obesity status (obese=non-obese) differed in frequency between the genotypes. Age, fat cell volume, BMI and WHR were also similar in the three genotypes.
We also analyzed the clinical phenotype in the subgroups. Firstly, we investigated all lean and obese separately. Age and gender were included in the ANCOVA. Secondly, we divided the group according to gender, including age and obesity status, in the ANCOVA. Finally, we analyzed obese men, lean men, obese women and lean women separately bearing in mind the limited number of Gly 388 Gly subjects which were 4, 6, 8 and 14, respectively, in these groups. No significant differences between genotypes were observed for BMI, WHR or fat cell volume in any of the subgroup analyses.
Lipolysis data
In order to obtain a sufficiently large number of subjects carrying each phenotype we first analyzed all subjects together. Because catecholamine-induced lipolysis is influenced by gender, age and obesity status, 2 all statistical calculations were corrected for these variables in the ANCOVA. We used obese=non-obese as an independent category variability instead of BMI, since the latter values were biomodally distributed (probably because we actively recruited obese subjects).
Lipolysis data for the whole cohort are shown in Table 2 . Neither lipolytic sensitivity (pD 2 ) or maximum lipolytic effect for any of the adrenergic agonists was influenced by the polymorphism. There was a borderline significant (P ¼ 0.054) effect of the polymorphism on basal glycerol release. This effect disappeared after adjustment for multiple comparison. We also divided the material in subgroups and analysed the data as described above for the clinical data. Lean and obese men and women and lean men, obese men, lean women and obese women were analyzed separately. There were no significant effects of genotype on lipolysis in any of the subgroups.
It should be noted that noradrenaline and CGP-12177 had less lipolytic effects than dobutamine or terbutaline ( Table 2 ). This is a well known phenomenon. 2 The latter two agents are full agonists, whereas CGP-12177 is only a partial agonist. Also, the action of noradrenaline on lipolysis is the net sum of b-adrenoceptor mediated lipolytic and a 2 -adrenoceptors-mediated antilipolytic effects. Table 3 . Maximum radioligand binding capacity (about 2 pmol=10 7 cells) and the proportions of b 1 =b 2 -adrenoceptors (about 50% each) did not differ between the genotypes. Furthermore, the affinity constants for the antagonist ICI 118 555 at b 1 -adrenoceptors (K d -low, about 1 mmol=l) or at b 2 -adrenoceptors (K d -high, about 10 nmol=l) were not influenced by the radioligand. Also the three different genotypes showed a similar binding affinity constant for the radioligand (about 100 pmol=l).
Discussion
This is the first functional study of the native Arg 389 and Gly 389 b 1 -adrenoceptor. The b 1 -adrenoceptor is important in energy homeostasis and thereby a good candidate gene for obesity. We investigated adipocytes because they can be easily obtained in large clinical material and because the b 1 -adrenoceptor can maximally stimulate lipolysis in human fat cells. 2 There is also an additional advantage with fat cells, namely the possibility to study interactions between several b-adrenoceptor subtypes (ie b 1 , b 2 and b 3 ) in the same cell population.
No difference was found between the Arg 389 and Gly 389 variants in the lipolytic sensitivity or maximum lipolytic effect for the natural ligand norepinephrine or the b 1 -agonist dobutamine. Likewise, the lipolytic action of b 2 -or b 3 -adrenoceptor selective agonists was not influenced by the polymorphism. A borderline effect of genotype on the basal rate of lipolysis was observed in the whole material. However, this was likely to have been a chance finding since it became statistically insignificant after adjustment for multiple comparison. No impact of the polymorphism was found on either the number or affinity of b 1 -or b 2 -adrenoceptors. We could not find any association between genotype and lipolysis when either the entire cohort was investigated or if the various subgroups were analyzed separately.
When the lipolysis and radioligand binding data were analyzed together, it is clear that the Arg 389 Gly polymorphism is not important for catecholamine-induced lipolysis in native human fat cells. It is well known that there are regional differences in adipocyte lipolysis with visceral fat cells being more lipolytic than subcutaneous fat cells following catecholamine stimulation. 2 However, we have no reason to believe that there are important regional adipose interactions with the Arg 389 Gly polymorphism and lipolysis, since there is a strong correlation between subcutaneous and visceral fat cells as regards pD 2 and the maximum lipolytic effect of b-adrenergic agonists. 11 However, it should be stressed that our data do not exclude the possibility that the polymorphism is important for b 1 -adrenoceptor function in other cells or for b 1 -adrenoceptor mediated events other than lipolysis. In transfected cells the polymorphism influences the coupling between the receptor and the G s protein resulting in altered adenylyl cyclase. 5 There are several steps between G s proteins and activation of hormone sensitive lipase which is the final step in lipolysis activation. 2 Compensatory mechanisms may be present in human fat cells which adjust lipolysis activation for the effects of amino acid variation at codon 389 on b 1 -adrenoceptor coupling of G-proteins. It is also possible that the b 1 -adrenoceptor couples in a different manner to Gproteins in cell lines as compared to in native human cells. Unfortunately it was not possible to also study adenylyl cyclase due to the lack of sufficient tissue amounts. From a clinical perspective though it is relevant to consider that the lipolytic effect of the major hormone, noradrenaline, was not influenced by genotype.
A Ser 49 Gly polymorphism has also been described in the b 1 -adrenoceptor gene. 3 To our knowledge no data on recombinant cells are available for this gene variant, although it is less likely to be functional since the variation between glycine and serine at position 49 is not predicted to cause a great variability in receptor function. 3 It is more likely that polymorphisms in other genes involved in lipolysis regulation can interact with the Arg 389 Gly variant in the b 1 -adrenoceptor gene and thereby influence lipolysis. For example, there are three functional polymorphisms in the b 2 -adrenoceptor gene, some of which influence lipolysis in human fat cells. 12 We made an attempt to study the influence of the polymorphism together with the Arg 389 Gly b 1 polymorphism on lipolysis. However, there was an abundance of different haplotypes and the number of subjects belonging to a particular haplotype was too small to allow a meaningful statistical comparison.
Little is known about the influence of the Arg 389 Gly polymorphism on clinical parameters. In this respect, it should be noted that a recent study showed no effect of the Arg 389 Gly polymorphism in dilated cardiomyopathy. 13 In the present study we observed no effect on obesity related parameters such as BMI, WHR and fat cell volume. Furthermore, the distribution of obese vs non-obese subjects did not differ between the phenotype. Thus, the polymorphism appears not to be of great importance for obesity. However, our study was not population-based and we cannot therefore In summary, this study shows that the native Arg 389 Gly polymorphism of the human b 1 -adrenoceptor does not influence lipolysis regulation in native human fat cells. This polymorphism has been reported to have effects in an artificial recombinant cell system. Therefore, caution should be exercised in extrapolating data on Arg 389 Gly polymorphism from cell systems to native cells.
